Category: Sponsors

BCC Provides Update on Health Canada Licensed Producer Application and Owen Sound Facility Build Out

by Todd | Oct 26, 2017 | Capital Markets, Consulting | 0 comments TORONTO, Oct. 26, 2017 (GLOBE NEWSWIRE) — The Canadian Bioceutical Corporation (the “Company” or “BCC”) (CSE:BCC) (OTC:CBICF) today announced it has completed preparatory construction work and commenced detailed planning for the full build-out of its cannabis cultivation facility in Owen Sound, as well as provided an update on its application with Health Canada to obtain Licensed Producer status under the Access to Cannabis for Medical Purposes Regulation (“ACMPR”). On January 7, 2015 the Company announced that its subsidiary, BioCannabis Products Ltd., had filed a Marijuana for Medical Purposes Regulations application with Health Canada, and subsequently updated its application under the ACMPR.  On August 23, 2017 the Company was advised that its application was at the Detailed Review and Initiation of Security Clearance Process stage. Consequently, BCC has decided to commence further planning for the build out of its facility. Preparatory work on power and certain other utility systems has been completed, and the Company has now commenced more detailed design work for completion of the facility.  The Company anticipates being ready to commence cultivation in the latter half of 2018 for final inspection by Health Canada.  No assurances can be given at this point on the timeframe for inspection and potential subsequent granting of Licensed Producer status. “Commencing the full build-out of our Owen Sound facility is...

Read More

World Health Organization Explores International Rescheduling of CBD at Expert Committee Meeting

by Todd | Oct 26, 2017 | General, Medical Cannabis, Pharma & Biotech, Research | 0 comments October 26, 2017 Raul Elizalde to speak before WHO Expert Committee on Drug Dependence review of the psychoactivity of CBD. On November 6th, the World Health Organization’s (WHO) Thirty-Ninth meeting of the Expert Committee on Drug Dependence will begin a 5-day agenda set to determine the potential for harm or dependance of 16 different substances, including cannabidiol (CBD). Medical Marijuana, Inc. subsidiary HempMeds® will have a representative speaking before the committee on the first day regarding CBD. While WHO recognizes the medical use of certain substances is indispensable in the treatment of many conditions and that they should be available to patients for such purposes, the committee is also tasked with determining which substances should be regulated or banned internationally as scheduled drugs. WHO has a part in two of the United Nation’s central drug control conventions – the 1961 Single Convention on Narcotic Drugs and 1971 Convention on Psychotropic substances. WHO is responsible for conducting the medical, scientific, and public health evaluation of potentially harmful substances to determine the UN’s role in regulating them. This is done through the thirteen member Expert Committee on Drug Dependence (ECDD). The committee is made up of an international panel of experts in the field of drug addiction and abuse. The ECDD evaluates the dependence-producing...

Read More

Study: Retail Cannabis Sales Associated With Fewer Opioid Deaths

SHARE THIS POST Thursday, 19 October 2017 Fort Worth, TX: Retail cannabis distribution in Colorado is associated with a reduction in opioid-related mortality, according to data published online ahead of print in The American Journal of Public Health. A team of investigators from the University of North Texas School of Public Health, the University of Florida, and Emory University compared changes in the prevalence of monthly opioid-related deaths before and after Colorado retailers began selling cannabis to adults. Researchers compared Colorado’s data with trends in neighboring states (that had not implemented any change in marijuana’s legal status), and also sought to control for recent changes in the state’s prescription drug monitoring program. Authors reported a 6.5 percent decrease in monthly opioid deaths following retail cannabis sales. They wrote: “Colorado’s legalization of recreational cannabis sales and use resulted in a 0.7 deaths per month reduction in opioid-related deaths. This reduction represents a reversal of the upward trend in opioid-related deaths in Colorado.” Authors concluded, “Legalization of cannabis in Colorado was associated with short-term reductions in opioid-related deaths.” Their data is consistent with prior studies finding that cannabis access is associated with reductions in prescription drug spending, opioid-related hospitalizations, and opioid-related fatalities. For more information, contact Paul Armentano, NORML Deputy Director, at paul@norml.org. Full text of the study, “Recreational cannabis legalization and opioid-related deaths in Colorado, 2000-2015,” appears in The American...

Read More

Revive Therapeutics Ltd. Announces Results for Fiscal Year Ended June 30, 2017

SHARE THIS POST TORONTO, ONTARIO–(Marketwired – Oct. 19, 2017) – Revive Therapeutics Ltd. (“Revive” or the “Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a company focused on the research, development and commercialization of novel treatments for serious and unmet medical needs in the medical cannabis and cannabinoid pharmaceuticals sectors, today announced its results for the fiscal year ended June 30, 2017. The Audited Financial Statements and Management’s Discussion and Analysis for the year ended June 30, 2017, may be viewed on SEDAR at www.sedar.com. “I am pleased with how our focus on developing and commercializing novel cannabinoid-based therapies has evolved over this past year,” said Craig Leon, Chief Executive Officer of Revive. “The value creating initiatives achieved for our medical cannabis and cannabinoid pharmaceuticals strategy such as the exclusive license and the research of cannabinoid-based therapies for liver diseases, the development of a unique delivery technology for cannabinoids, the relationships with scientific advisors, academia and industry, and the potential of future collaborations with companies seeking to develop and commercialize novel cannabinoid-based therapies effectively positions Revive in the medical cannabis and cannabinoid pharmaceuticals space for broad and large market opportunities.” Over the past year Revive has been focused on developing novel therapies that target the endocannabinoid system and building a robust cannabinoid-based product pipeline which includes early stage research and development programs with the advancement of cannabinoid-based therapies for liver diseases and potentially...

Read More

Emerald Health’s Two Cannabis Production Expansion Sites Progressing for Legalized Adult-Use Market in 2018

SHARE THIS POST Emerald submits applications to Health Canada for two significant production expansion projects, including one of Canada’s largest-scale greenhouse operations Victoria, BC, October 18, 2017 – Emerald Health Therapeutics Inc. (“EHT”) (TSXV: EMH; OTCQX: EMHTF), through Emerald Health Botanicals Inc. (“Emerald”), its wholly owned subsidiary and a Licensed Producer under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”), has submitted license applications to Health Canada for approval of two new growing sites. Emerald is preparing for the large-scale production of cannabis in anticipation of legalization of the adult-use cannabis market on July 1, 2018. In September, Emerald filed an application to Health Canada for its Pure Sunfarms’ Delta, BC facility, which is a partnership with Village Farms (TSXV: VFF). This partnership combines Emerald’s extensive medical cannabis growing experience and broad portfolio of cannabis genetics with Village Farms’ many decades of greenhouse growing expertise and large-scale, quality, low-cost production of an array of plant products and a currently producing, highly efficient 25-acre, 1.1 million square feet greenhouse facility. Emerald and Village Farms are retrofitting this greenhouse from tomato growing into a configuration optimized for largescale cannabis cultivation. With a key goal of the partnership to be a large, very low-cost cannabis producer, Pure Sunfarms also optioned from Village Farms an additional 3.7 million square feet of existing highly efficient greenhouse space in the same Delta complex. In...

Read More